Risk of Delays, Interruptions or Discontinuation of Research and Development
First written in FY2017. 1 of 4 entries say "Materialised", first in FY2019. Latest entry: FY2022.
Fuji Pharma moved to the "Worse" side of this theme in 2019, 4 years before the typical company in this theme (2023).
The whole theme swung hardest in 2025: 3 of 22 companies on the "Worse" side.
6 other companies' latest entry also says "Mitigated".
- FY2022MitigatedAnnual report
「As one measure, the Company is working to minimise the impact of risks by including provisions in contracts with external parties setting out responses to problems when they arise.」
As an additional measure addressing research and development risks arising not only from the Company but also from problems at joint development partners, alliance partners and contractors, the Company includes responses to problems in contractual provisions. - FY2021WorsenedAnnual report
「Problems in the Group's research and development, such as failure to obtain the expected results in clinical trials or the revision of development plans following comments from regulatory authorities, as well as problems arising at external parties such as joint development partners, alliance partners and contractors, may cause new products under development and other research and development projects not to proceed as planned. This may result in higher costs due to changes to plans, an extension of the development period, or the discontinuation or suspension of development, which could affect the Group's business performance.」
In addition to the conventional risk of delays in the Company's own research and development, risks arising from external parties such as joint development partners, alliance partners and contractors are explicitly identified. - FY2019MaterialisedAnnual report
「The main reasons were a decline in revenue resulting from the discontinuation of development of products under development, the transfer of branded contrast media, including Optiray, and a decline in the market share of core products due to the launch of generic products by other companies.」
The Company states that the discontinuation of development of a product under research and development actually occurred as one of the main reasons for the decline in revenue. - FY2017First statedAnnual report
「If research and development of a new product does not proceed as planned, the development period may be extended, or development may be suspended or discontinued, which could affect the Group's business performance.」
The impact on business performance of research and development of new products not proceeding as planned is stated.